Full Press Release Details
Aytu BioScience Announces China Export Clearance of Company's
COVID-19 IgG/IgM Rapid Test
500,000 Rapid Tests Cleared for Shipment to Company's
CO / ACCESSWIRE / April 30, 2020 / Aytu BioScience, Inc. (NASDAQ:
AYTU) (the Company ), a specialty pharmaceutical
company focused on commercializing novel products that address
significant patient needs announced today that it has received
confirmation of export approval for product shipment by
China's Ministry of Commerce for the Company's COVID-19
Disbrow, Chief Executive Officer of Aytu BioScience, commented,
The backlog of medical products being exported from China
created a shipment delay, but Aytu's next 500,000 rapid tests
have now been cleared for shipment to the U.S. This export
clearance from China, along with the additional supply we have
secured through our new relationship with Biolidics, gives us great
confidence in our supply chain and ability to provide these needed
test kits to the U.S. medical community. Our shipments remain on
track for delivery and, upon receipt, will be distributed to U.S.
About Aytu BioScience, Inc.
BioScience, Inc. is a commercial-stage specialty pharmaceutical
company focused on commercializing novel products that address
significant patient needs. The Company currently markets a
portfolio of prescription products addressing large primary care
and pediatric markets. The primary care portfolio includes (i)
Natesto , the only FDA-approved nasal formulation of
testosterone for men with hypogonadism (low testosterone, or "Low
T"), (ii) ZolpiMist , the only FDA-approved oral spray
prescription sleep aid, and (iii) Tuzistra XR, the only
FDA-approved 12-hour codeine-based antitussive syrup. The pediatric
portfolio includes (i) AcipHex Sprinkle , a granule
formulation of rabeprazole sodium, a commonly prescribed proton
pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin
antibiotic suspension; (iii) Karbinal ER, an extended-release
carbinoxamine (antihistamine) suspension indicated to treat
numerous allergic conditions; and (iv) Poly-Vi-Flor and
Tri-Vi-Flor , two complementary prescription fluoride-based
supplement product lines containing combinations of fluoride and
vitamins in various for infants and children with fluoride
deficiency. Aytu recently acquired exclusive U.S. distribution
rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is
a solid phase immunochromatographic assay used in the rapid,
qualitative and differential detection of IgG and IgM antibodies to
the 2019 Novel Coronavirus in human whole blood, serum or plasma.
This point-of-care test has been validated in a 126 patient
clinical trial in China and has received CE marking.
recently acquired Innovus Pharmaceuticals, a specialty
pharmaceutical company commercializing, licensing and developing
safe and effective consumer healthcare products designed to improve
men's and women's health and vitality. Innovus commercializes over
thirty-five consumer health products competing in large healthcare
categories including diabetes, men's health, sexual wellness and
respiratory health. The Innovus product portfolio is commercialized
through direct-to-consumer marketing channels utilizing the
Company's proprietary Beyond Human marketing and sales
strategy is to continue building its portfolio of
revenue-generating products, leveraging its focused commercial team
and expertise to build leading brands within large therapeutic
markets. For more information visit aytubio.com and visit
innovuspharma.com to learn about the Company's consumer healthcare
Contact for Media and